Fosamax and Osteonecrosis of the Jaw: Risk, Causation, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Assessment

The legacy of general health and science communication has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this tradition, the dissemination of information about pharmaceuticals has emphasized balanced perspectives, drawing from established clinical knowledge and population-level data. This heritage provides a critical framework for examining emerging concerns that bridge broad health awareness with more focused risk assessment. Transitioning from this general context, attention now turns to a specific area of inquiry: the relationship between bisphosphonate therapy, particularly Fosamax, and the risk of osteonecrosis of the jaw. While the initial health discourse centered on the drug's efficacy in treating osteoporosis, subsequent observations have prompted a more targeted examination of potential adverse outcomes. This pivot requires careful consideration of exposure patterns, patient populations, and the temporal dynamics of risk. The shift from general health information to occupational exposure concern necessitates a refined analytical lens. Here, the focus moves beyond broad patient education to scrutinize the conditions under which exposure occurs, the duration and intensity of use, and the demographic factors that may influence susceptibility. This transition respects the foundational principles of health communication while advancing a more precise inquiry into the specific risk profile associated with Fosamax and osteonecrosis of the jaw.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation of ONJ typically involves delayed healing after tooth extraction, local infection, or spontaneous bone exposure. The condition is generally associated with invasive dental procedures, such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis relies on clinical examination and imaging, with multiscale characterization of jawbone providing comprehensive information to help understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Epidemiological Evidence

Known risk factors for ONJ include diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, and angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ involve its antiresorptive action, which suppresses bone turnover. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone remodeling. In the jawbone, which has high remodeling rates and is subject to microtrauma from chewing, this suppression can impair healing and lead to necrosis. The multiscale characterization of jawbone helps elucidate these site-specific responses (https://pubmed.ncbi.nlm.nih.gov/40345077/). The risk of ONJ may increase with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Temporal Relationship and Causation Considerations

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, indicating that not all jaw symptoms in treated patients are attributable to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Clinical Management and Summary of Evidence

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors. The label acknowledges that ONJ can occur spontaneously but is generally associated with dental procedures or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer exposure, and discontinuation reduces risk (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, management includes discontinuing Fosamax if severe symptoms develop, and most patients experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Rechallenge may lead to recurrence, suggesting a causal link in susceptible individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, studies show that Fosamax use is associated with an increased risk of ONJ, particularly with longer treatment duration and in the presence of dental procedures or other risk factors. The absolute risk remains low, but the condition is serious. Warnings in the prescribing information address this risk, and clinical management includes monitoring, dental evaluation, and consideration of drug discontinuation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of developing osteonecrosis of the jaw from Fosamax?

The absolute risk of ONJ in patients taking Fosamax for osteoporosis is low, approximately 0.05% after 5 years of use. However, the risk increases with longer treatment duration, being threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, reducing bone remodeling. The jawbone has high remodeling rates and is subject to microtrauma from chewing, so suppression of bone turnover can impair healing and lead to necrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the warning signs of osteonecrosis of the jaw?

Warning signs include delayed healing after tooth extraction, local infection, spontaneous bone exposure, or persistent jaw pain. Patients should seek dental evaluation if these symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.